Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs Midi Health

Elara MD
Graded #467

Lower grade

vs+2.8999999999999986
Midi Health
Graded #414

Higher grade

The verdict

Midi Health takes it — 56.4/100 to 53.5/100.

Midi Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Midi Health is a nationwide 50-state menopause and perimenopause telehealth platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMidi Health +5
40
45
Dose & formulationElara MD +14
54
40
Clinical oversightMidi Health +15
63
78
Labs & monitoringEven
52
52
FulfillmentMidi Health +12
66
78
Contract termsEven
55
55
Elara MD · left barMidi Health · right bar

The numbers

MetricElara MDMidi Health
WeighScore53.5/10056.4/100
GradeCC
Scorecard rank#467#414
Semaglutide$249/mo (0.2 mg dose, compounded)Not disclosed
Tirzepatide$349/mo (2.0 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Elara MD

Graded #467 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
Midi Health

Graded #414 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard